Vaxart COVID-19 vaccine shows encouraging action in animal study

• Vaxart (NASDAQ:VXRT) jumps 20% in premarket, in reaction to additional data from a preclinical study evaluating its COVID-19 vaccine candidate.
• Results showed a significant 4-5 log (10, 000x - 100,000x) reduction in lung viral load in hamsters that received two oral doses compared to non-vaccinated animals.
• The data also showed comparable mucosal protection between intranasal and oral routes of administration.
• As previously announced, all hamsters that received two oral doses of Vaxart’s COVID-19 vaccine candidate showed no systemic weight loss. Whereas, the unvaccinated animals lost ~9% total weight. Additionally, unvaccinated hamsters had over 2x the relative lung weight of orally vaccinated hamsters.
• https://seekingalpha.com/news/3635501-vaxart-covidminus-19-vaccine-shows-encouraging-action-in-animal-study